United States
Every company in the roster headquartered in United States.
Every company in the roster headquartered in United States.
441 of 441 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Retension PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | RTN-001Phase 2 · Hypertension | Mar 2027RTN-001 · Phase 2 | — | — | — | — |
Rgene CorporationPrivate | 1 asset: 1 Ph 2 | BLEX 404Phase 1/2 · Non-Small Cell Lung Cancer | 30 Apr 2027BLEX 404 · Phase 2 | — | — | — | — |
Rise TherapeuticsPrivate | 1 asset: 1 Ph 1 | R-3750Phase 1 · Ulcerative Colitis | 30 Apr 2028R-3750 · Phase 1 | — | — | — | — |
River 2 RenalPrivate | 1 asset: 1 Ph 2 | R2R01Phase 2 · Heart FailureWeak signal | 1 Apr 2027R2R01 · Phase 2 | — | — | — | — |
Rivus PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | HU6Phase 2 · Heart FailurePartial signal | Feb 2027HU6 · Phase 2 | — | — | — | — |
Rondo TherapeuticsPrivate | 1 asset: 1 Ph 1 | RNDO-564Phase 1 · Non-Small Cell Lung Cancer | 28 Feb 2029RNDO-564 · Phase 1 | — | — | — | — |
Salubris Biotherapeutics IncPrivate | 1 asset: 1 Ph 2 | JK08Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
Sardocor (Medera Biopharma)Private | 1 asset: 1 Ph 2 | AAV1.SERCA2aPhase 1/2 · Heart Failure | Oct 2027AAV1.SERCA2a · Phase 1 | — | — | — | — |
Sarfez PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
SatRxPrivate | 1 asset: 1 Ph 3 | GosogliptinPhase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
Scilex BioPrivate | 1 asset: 1 Ph 2 | TisolagilinePhase 2 · Obesity | 31 Jan 2027Tisolagiline · Phase 2 | — | — | — | — |
scPharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | $41MJun 2025 | Ended Jan 2026 | $15M |
SeagenPrivate | 5 assets: 2 approved, 2 Ph 3, 1 Ph 1 | Fetrastobart vedotinPhase 3 · Non-Small Cell Lung Cancer | 5 Jan 2028Fetrastobart vedotin · Phase 1 | — | — | — | — |
Second Life TherapeuticsPrivate | 1 asset: 1 Ph 2 | SL-28Phase 1/2 · Non-Small Cell Lung Cancer | 1 Jan 2027SL-28 · Phase 1/2 | — | — | — | — |
Secretome TherapeuticsPrivate | 1 asset: 1 Ph 1 | STM01Phase 1 · Heart Failure | None on record | — | — | — | — |
Seismic PharmaPrivate | 1 asset: 1 Ph 3 | IstaroximePhase 2/3 · Heart FailurePartial signal | Dec 2028Istaroxime · Phase 2/3 | — | — | — | — |
Seismic TherapeuticPrivate | 1 asset: 1 Ph 1 | S-4321Phase 1 · Psoriatic Arthritis | Sep 2027S-4321 · Phase 1 | — | — | — | — |
Simcha IL-18, Inc.Private | 1 asset: 1 Ph 2 | VevoctadekinPhase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Solu Therapeutics, IncPrivate | 1 asset: 1 Ph 1 | STX-0712Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026STX-0712 · Phase 1 | — | — | — | — |
Sorriso PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | SOR102Phase 1 · Ulcerative ColitisWeak signal | None on record | — | — | — | — |
Sparrow PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | clofutribenPhase 2 · Type 2 DiabetesWeak signal | 31 Dec 2027clofutriben · Phase 2 | — | — | — | — |
SpinogenixPrivate | 1 asset: 1 Ph 3 | Tazbentetol (SPG302)Phase 2/3 · Amyotrophic Lateral Sclerosis | 31 Dec 2027Tazbentetol (SPG302) · Phase 2/3 | — | — | — | — |
SynthekinePrivate | 1 asset: 1 Ph 2 | STK-012Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2029STK-012 · Phase 1/2 | — | — | — | — |
T3D TherapeuticsPrivate | 1 asset: 1 Ph 3 | T3D-959Phase 2/3 · Alzheimer's DiseasePartial signal | Apr 2031T3D-959 · Phase 2/3 | — | — | — | — |
Teligene USPrivate | 1 asset: 1 Ph 2 | SutetinibPhase 2 · Non-Small Cell Lung Cancer | Dec 2027Sutetinib · Phase 2 | — | — | — | — |
TerSera Therapeutics LLCPrivate | 2 assets: 2 approved | Approved assets only | 30 Mar 2027Goserelin · Phase 1 | — | — | — | — |
Therini Bio, Inc.Private | 1 asset: 1 Ph 1 | THN391Phase 1 · Alzheimer's Disease | 31 Mar 2027THN391 · Phase 1 | — | — | — | — |
TriGemX BioPrivate | 1 asset: 1 Ph 3 | ElismetrepPhase 3 · Migraine | Feb 2027Elismetrep · Phase 3 | — | — | — | — |
Valorum Biologics LLCPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Vantive HealthPrivate | 1 asset: 1 Ph 3 | Icodextrin (peritoneal ultrafiltration)Phase 3 · Heart FailureWeak signal | None on record | — | — | — | — |
Vasa TherapeuticsPrivate | 1 asset: 1 Ph 1 | Vasa Therapeutics VS-041Phase 1 · Heart Failure | Nov 2026Vasa Therapeutics VS-041 · Phase 1 | — | — | — | — |
VentrixPrivate | 1 asset: 1 Ph 1 | VentriGelPhase 1 · Heart FailureWeak signal | None on record | — | — | — | — |
VERO BiotechPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Virogenics, Inc.Private | 1 asset: 1 Ph 1 | CMS121Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Vivace Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | VT3989Phase 1/2 · Non-Small Cell Lung Cancer | 1 May 2028VT3989 · Phase 3 | — | — | — | — |
VIVUSPrivate | 2 assets: 1 approved, 1 Ph 3 | Extended-release tacrolimus (VI-0106)Phase 3 · Pulmonary Arterial Hypertension | 31 May 2028Extended-release tacrolimus (VI-0106) · Phase 3 | — | — | — | — |
VM Oncology, LLCPrivate | 1 asset: 1 Ph 2 | VMD-928Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2027VMD-928 · Phase 1/2 | — | — | — | — |
Volastra Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | OrvanesibPhase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Vyriad, Inc.Private | 1 asset: 1 Ph 2 | VSV-IFNβ-NISPhase 2 · Melanoma | None on record | — | — | — | — |
XYone Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | XYA02Phase 1/2 · Non-Small Cell Lung Cancer | 15 Sep 2029XYA02 · Phase 1/2 | — | — | — | — |
Zumutor Biologics Inc.Private | 1 asset: 1 Ph 1 | ZM008Phase 1 · Non-Small Cell Lung Cancer | Dec 2026ZM008 · Phase 1 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.